Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.

Greally M, Chou JF, Chatila WK, Margolis M, Capanu M, Hechtman JF, Tuvy Y, Kundra R, Daian F, Ladanyi M, Kelsen DP, Ilson DH, Berger MF, Tang LH, Solit DB, Diaz LA Jr, Schultz N, Janjigian YY, Ku GY.

Clin Cancer Res. 2019 Jul 23. doi: 10.1158/1078-0432.CCR-18-3603. [Epub ahead of print]

PMID:
31337644
2.

Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases.

Chen Y, Cheng X, Song H, Wu AJ, Ku GY, Lee P, Slingerland M, Koyanagi K, Ke S, Qiu H, Shi W, Gao Y, Chen J; written on behalf of AME Radiation Oncology Collaborative Group.

J Thorac Dis. 2019 Apr;11(4):1536-1545. doi: 10.21037/jtd.2019.03.10.

3.

Maximizing response: a case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma.

Greally M, Agarwal R, El Dika I, Shamseddine A, El-Olayan A, Haibe Y, Paroder V, Shia J, Abou-Alfa GK, Ku GY.

J Gastrointest Oncol. 2019 Apr;10(2):367-372. doi: 10.21037/jgo.2018.10.07.

4.

Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer.

Won E, Basunia A, Chatila WK, Hechtman JF, Chou JF, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Tuvy Y, Berger MF, Tang L, Kelsen DP, Schattner M, Ilson DH, Capanu M, Solit DB, Schultz N, Janjigian YY.

Clin Cancer Res. 2019 Jul 1;25(13):3811-3817. doi: 10.1158/1078-0432.CCR-18-3789. Epub 2019 Apr 5.

PMID:
30952642
5.

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway.

Ku GY.

Oncology (Williston Park). 2019 Mar 13;33(3):110-2. No abstract available.

6.

The Current Status of Immunotherapies in Esophagogastric Cancer.

Ku GY.

Hematol Oncol Clin North Am. 2019 Apr;33(2):323-338. doi: 10.1016/j.hoc.2018.12.007. Review.

PMID:
30833003
7.

Immune checkpoint inhibitors in esophagogastric adenocarcinoma: do the results justify the hype?

Greally M, Ku GY.

J Thorac Dis. 2018 Dec;10(12):6407-6411. doi: 10.21037/jtd.2018.12.01. No abstract available.

8.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT.

Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.

PMID:
30643254
9.

Comment on "Microsatellite Instability as a Predictive Biomarker for Adjuvant Chemotherapy in Gastric Cancer": Are we There Yet?

Mondaca S, Yoon SS, Strong VE, Ku GY, Ilson DH, Greally M, Janjigian YY.

Ann Surg. 2019 Aug;270(2):e39-e40. doi: 10.1097/SLA.0000000000003100. No abstract available.

PMID:
30480560
10.

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY.

Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21.

PMID:
30463996
11.

Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders.

Greally M, Chou JF, Molena D, Rusch VW, Bains MS, Park BJ, Wu AJ, Goodman KA, Kelsen DP, Janjigian YY, Ilson DH, Ku GY.

J Thorac Oncol. 2019 Mar;14(3):540-546. doi: 10.1016/j.jtho.2018.10.152. Epub 2018 Nov 1.

PMID:
30391577
12.

Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience.

Nobel TB, Barbetta A, Hsu M, Tan KS, Pinchinat T, Schlottmann F, Bains MS, Ku GY, Wu AJ, Patti MG, Jones DR, Molena D.

J Gastrointest Surg. 2019 Jan;23(1):11-22. doi: 10.1007/s11605-018-3958-8. Epub 2018 Sep 13.

PMID:
30215197
13.

Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.

Mondaca S, Margolis M, Sanchez-Vega F, Jonsson P, Riches JC, Ku GY, Hechtman JF, Tuvy Y, Berger MF, Shah MA, Kelsen DP, Ilson DH, Yu K, Goldberg Z, Epstein AS, Desai A, Chung V, Chou JF, Capanu M, Solit DB, Schultz N, Janjigian YY.

Gastric Cancer. 2019 Mar;22(2):355-362. doi: 10.1007/s10120-018-0861-7. Epub 2018 Aug 7.

PMID:
30088161
14.

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.

Glassman DC, Palmaira RL, Covington CM, Desai AM, Ku GY, Li J, Harding JJ, Varghese AM, O'Reilly EM, Yu KH.

BMC Cancer. 2018 Jun 27;18(1):693. doi: 10.1186/s12885-018-4605-1.

15.

Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.

Barbetta A, Hsu M, Tan KS, Stefanova D, Herman K, Adusumilli PS, Bains MS, Bott MJ, Isbell JM, Janjigian YY, Ku GY, Park BJ, Wu AJ, Jones DR, Molena D.

J Thorac Cardiovasc Surg. 2018 Jun;155(6):2710-2721.e3. doi: 10.1016/j.jtcvs.2018.01.086. Epub 2018 Feb 15.

16.

Systemic therapy for esophagogastric cancer: immune checkpoint inhibition.

Lyons TG, Ku GY.

Chin Clin Oncol. 2017 Oct;6(5):53. doi: 10.21037/cco.2017.09.03.

17.

Systemic therapy for esophageal cancer: chemotherapy.

Ku GY.

Chin Clin Oncol. 2017 Oct;6(5):49. doi: 10.21037/cco.2017.07.06. Review.

18.

Systemic therapy for esophagogastric cancer: targeted therapies.

Lyons TG, Ku GY.

Chin Clin Oncol. 2017 Oct;6(5):48. doi: 10.21037/cco.2017.07.02. Review.

19.

Preface on Esophagus Cancer.

Ku GY, Ilson DH.

Chin Clin Oncol. 2017 Oct;6(5):44. doi: 10.21037/cco.2017.10.04. No abstract available.

20.

Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.

Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, Riches JC, Tuvy Y, Kundra R, Bouvier N, Vakiani E, Gao J, Heins ZJ, Gross BE, Kelsen DP, Zhang L, Strong VE, Schattner M, Gerdes H, Coit DG, Bains M, Stadler ZK, Rusch VW, Jones DR, Molena D, Shia J, Robson ME, Capanu M, Middha S, Zehir A, Hyman DM, Scaltriti M, Ladanyi M, Rosen N, Ilson DH, Berger MF, Tang L, Taylor BS, Solit DB, Schultz N.

Cancer Discov. 2018 Jan;8(1):49-58. doi: 10.1158/2159-8290.CD-17-0787. Epub 2017 Nov 9.

21.

Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.

Vellayappan BA, Soon YY, Ku GY, Leong CN, Lu JJ, Tey JC.

Cochrane Database Syst Rev. 2017 Aug 22;8:CD010511. doi: 10.1002/14651858.CD010511.pub2. Review.

22.

The Current Status of Immunotherapies in Esophagogastric Cancer.

Ku GY.

Surg Oncol Clin N Am. 2017 Apr;26(2):277-292. doi: 10.1016/j.soc.2016.10.012. Review.

PMID:
28279469
23.

Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers.

Ku GY.

Surg Oncol Clin N Am. 2017 Apr;26(2):241-256. doi: 10.1016/j.soc.2016.10.009. Epub 2017 Feb 9. Review.

PMID:
28279467
24.

Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma.

Ku GY, Bains MS, Park DJ, Janjigian YY, Rusch VW, Rizk NP, Yoon SS, Millang B, Capanu M, Goodman KA, Ilson DH.

J Gastrointest Oncol. 2016 Dec;7(6):828-837. doi: 10.21037/jgo.2016.08.09.

25.

Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.

Ku GY, Kriplani A, Janjigian YY, Kelsen DP, Rusch VW, Bains M, Chou J, Capanu M, Wu AJ, Goodman KA, Ilson DH.

Cancer. 2016 Jul 1;122(13):2083-90. doi: 10.1002/cncr.30028. Epub 2016 May 6.

26.

Long-Term Survival With Salvage Surgery for Recurrent Esophageal Adenocarcinoma After Chemoradiotherapy.

Ku GY, Ilson DH.

J Clin Oncol. 2015 Nov 20;33(33):3854-7. doi: 10.1200/JCO.2015.62.6796. Epub 2015 Aug 31. No abstract available.

PMID:
26324375
27.

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.

Janjigian YY, Vakiani E, Ku GY, Herrera JM, Tang LH, Bouvier N, Viale A, Socci ND, Capanu M, Berger M, Ilson DH.

PLoS One. 2015 Aug 14;10(8):e0134731. doi: 10.1371/journal.pone.0134731. eCollection 2015.

28.

Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma.

Park DJ, Seo AN, Yoon C, Ku GY, Coit DG, Strong VE, Suh YS, Lee HS, Yang HK, Kim HH, Yoon SS.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1508-15. doi: 10.1245/s10434-015-4790-y. Epub 2015 Aug 11.

29.

Emerging mAbs for the treatment of esophagogastric cancer.

Ku GY, Ilson DH.

Expert Opin Emerg Drugs. 2015 Mar;20(1):63-74. doi: 10.1517/14728214.2015.983072. Epub 2014 Dec 6. Review.

PMID:
25483267
30.

Management of gastric cancer.

Ku GY, Ilson DH.

Curr Opin Gastroenterol. 2014 Nov;30(6):596-602. doi: 10.1097/MOG.0000000000000115. Review.

PMID:
25197781
31.

Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.

Park DJ, Yoon C, Thomas N, Ku GY, Janjigian YY, Kelsen DP, Ilson DH, Goodman KA, Tang LH, Strong VE, Coit DG, Yoon SS.

Ann Surg Oncol. 2014 Apr;21(4):1130-7. doi: 10.1245/s10434-013-3429-0. Epub 2013 Dec 27.

PMID:
24370903
32.

Adjuvant (postoperative) therapy for esophageal cancer.

Ku GY, Ilson DH.

Thorac Surg Clin. 2013 Nov;23(4):525-33. doi: 10.1016/j.thorsurg.2013.07.008. Review.

PMID:
24199702
33.

Depression, cytokines, and pancreatic cancer.

Breitbart W, Rosenfeld B, Tobias K, Pessin H, Ku GY, Yuan J, Wolchok J.

Psychooncology. 2014 Mar;23(3):339-45. doi: 10.1002/pon.3422. Epub 2013 Oct 18.

34.

Emerging tyrosine kinase inhibitors for esophageal cancer.

Ku GY, Ilson DH.

Expert Opin Emerg Drugs. 2013 Jun;18(2):219-30. doi: 10.1517/14728214.2013.805203. Review.

PMID:
23725567
35.

Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma.

Yuan J, Ku GY, Adamow M, Mu Z, Tandon S, Hannaman D, Chapman P, Schwartz G, Carvajal R, Panageas KS, Houghton AN, Wolchok JD.

J Immunother Cancer. 2013 Nov 18;1:20. doi: 10.1186/2051-1426-1-20. eCollection 2013.

36.

Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.

Janjigian YY, Ku GY, Campbell JC, Shah MA, Capanu M, Kelsen DP, Ilson DH.

Am J Clin Oncol. 2014 Apr;37(2):126-30. doi: 10.1097/COC.0b013e318271b14f.

PMID:
23211227
37.

Chemotherapeutic options for gastroesophageal junction tumors.

Ku GY, Ilson DH.

Semin Radiat Oncol. 2013 Jan;23(1):24-30. doi: 10.1016/j.semradonc.2012.09.003. Review.

PMID:
23207044
38.

Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus.

Ku GY, Ilson DH.

Gastrointest Cancer Res. 2012 May;5(3):85-92.

39.

Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.

Ku GY, Haaland BA, de Lima Lopes G Jr.

Cancer Chemother Pharmacol. 2012 Aug;70(2):231-8. doi: 10.1007/s00280-012-1898-7. Epub 2012 Jun 15.

PMID:
22699811
40.

Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.

Ilson DH, Minsky BD, Ku GY, Rusch V, Rizk N, Shah M, Kelsen DP, Capanu M, Tang L, Campbell J, Bains M.

Cancer. 2012 Jun 1;118(11):2820-7. doi: 10.1002/cncr.26591. Epub 2011 Oct 11.

41.

Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: a case series.

Ku GY, De Lima Lopes G Jr, Chang AY.

Asia Pac J Clin Oncol. 2011 Jun;7(2):174-9. doi: 10.1111/j.1743-7563.2010.01345.x. Epub 2010 Dec 22.

PMID:
21585698
42.

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.

Ku GY, Haaland BA, de Lima Lopes G Jr.

Lung Cancer. 2011 Dec;74(3):469-73. doi: 10.1016/j.lungcan.2011.04.008. Epub 2011 May 11.

PMID:
21565418
43.

Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity.

Ku GY, Chopra A, Lopes Gde L Jr.

Lung Cancer. 2010 Nov;70(2):223-5. doi: 10.1016/j.lungcan.2010.08.012.

PMID:
20817304
44.

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.

Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD.

Cancer. 2010 Apr 1;116(7):1767-75. doi: 10.1002/cncr.24951.

45.

Esophagogastric cancer: targeted agents.

Ku GY, Ilson DH.

Cancer Treat Rev. 2010 May;36(3):235-48. doi: 10.1016/j.ctrv.2009.12.009. Epub 2010 Feb 1. Review.

PMID:
20122806
46.

Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.

Yuan J, Page DB, Ku GY, Li Y, Mu Z, Ariyan C, Gallardo HF, Roman RA, Heine AI, Terzulli SL, Ritter E, Gnjatic S, Ritter G, Jungbluth AA, Allison JP, Old LJ, Wolchok JD.

Cancer Immun. 2010 Jan 7;10:1. Erratum in: Cancer Immun. 2010 Feb 24;10:5. Ritter, Erika [added].

47.

Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses.

Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, Xu Y, Terzulli SL, Old LJ, Allison JP, Houghton AN, Wolchok JD, Yuan J.

Cytotherapy. 2009;11(7):912-22. doi: 10.3109/14653240903136987.

48.

Role of neoadjuvant therapy for esophageal adenocarcinoma.

Ku GY, Ilson DH.

Surg Oncol Clin N Am. 2009 Jul;18(3):533-46. doi: 10.1016/j.soc.2009.03.004. Review.

PMID:
19500742
49.

Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.

Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, Houghton AN, Wolchok JD.

Cancer Immun. 2009 Jun 5;9:5.

50.

Preoperative therapy for esophageal cancer.

Ku GY, Ilson DH.

Gastroenterol Clin North Am. 2009 Mar;38(1):135-52, ix. doi: 10.1016/j.gtc.2009.01.012.

PMID:
19327572

Supplemental Content

Support Center